A strategy for early-risk predictions of clinical drug–drug interactions involving the GastroPlus^TM DDI module for time-dependent CYP inhibitors

References

• Albaugh DR, Fullenwider CL, Fisher MB, Hutzler JM. (2012). Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems. Drug Metab Disp 40:1336–44
   PubMed Web of Science ®Google Scholar
• Atkinson A, Kenny JR, Grime K. (2005). Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Disp 33:1637–47
   PubMed Web of Science ®Google Scholar
• Berry LM, Zhao Z. (2008). An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2:51–9
   PubMedGoogle Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working G, Evaluation FDACfD, and Research, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Disp 31:815–32
   PubMed Web of Science ®Google Scholar
• Blobaum A. (2006). Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome P450 enzymes?. Drug Metab. Dispos 34:1–7
   PubMed Web of Science ®Google Scholar
• Chu X, Cai X, Cui D, et al. (2013). In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 41:668–81
   PubMed Web of Science ®Google Scholar
• Garg V, Kauffman RS, Beaumont M, Heeswijk RPG. (2012). Telaprevir: pharmacokinetics and drug interactions. Antivir Ther 17:1211–21
   PubMed Web of Science ®Google Scholar
• Grime KH, Bird J, Ferguson D, Riley RJ. (2009). Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36:175–91
   PubMed Web of Science ®Google Scholar
• Grimm SW, Einolf HJ, Hall SD, et al. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Disp 37:1355–70
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. (2006). Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724–6
   PubMed Web of Science ®Google Scholar
• Kenny JR. (2012). Drug-drug interaction potential of marketed oncology drugs: In vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res 29:1960–76
   PubMed Web of Science ®Google Scholar
• Koenigs LL, Peter RM, Thompson SJ, et al. (1997). Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos 25:1407–15
   PubMed Web of Science ®Google Scholar
• Lim HK, Duczak N, Jr., Brougham L, et al. (2005). Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Disp 33:1211–9
   PubMed Web of Science ®Google Scholar
• Mao J, Johnson TR, Shen Z, Yamazaki S. (2013). Prediction of crizotinib-midazolam interaction using the simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos 41:343–52
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. (2000). An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos 28:1031–7
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Berry AJ, Kenny JR, et al. (2006). Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Disp 34:1291–300
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos 35:246–55
   PubMed Web of Science ®Google Scholar
• Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ. (1981). Diazepam interaction with antituberculosis drugs. Clin Pharmacol Ther 29:671–8
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Yerino P, Kazmi F, et al. (2011). The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Disp 39:2020–33
   PubMed Web of Science ®Google Scholar
• Park MH, Shin SH, 1 Byeon JJ, et al. (2017). Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: a case study of caffeine and ciprofloxacin. Korean J Physiol Pharmacol 21:107–15
   PubMed Web of Science ®Google Scholar
• Polasek TM, Elliot DJ, Somogyi AA, et al. (2006a). An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 61:570–84
   PubMed Web of Science ®Google Scholar
• Polasek TM, Miners JO. (2006b). Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 62:203–8
   PubMed Web of Science ®Google Scholar
• Rowland YK, Walsky RL, Jamei M, et al. (2011). Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 43:160–73
   PubMed Web of Science ®Google Scholar
• Sager JE, Lutz JD, Foti RS, et al. (2014). Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther 95:653–62
   PubMed Web of Science ®Google Scholar
• Sinha VK, Snoeys J, Osselaer NV, et al. (2012). From preclinical to human–prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos 33:111–21
   PubMed Web of Science ®Google Scholar
• Stresser DM, Mao J, Kenny JR, et al. (2014). Exploring concepts of in vitro time-dependent CYP inhibition assays. Expert Opin Drug Metab Toxicol 10:157–74
   PubMed Web of Science ®Google Scholar
• Tarrus E, Cami J, Roberts DJ, et al. (1987). Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9–18
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Tolonen A, Uusitalo J, et al. (2005). Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77:553–59
   PubMed Web of Science ®Google Scholar
• U.S Food and Drug Administration. (2012). Guidance for Industry: Drug interaction studies—Study design, data analysis, implications for dosing, and labeling recommendations (Draft guidance). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Silver Spring, US. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf
   Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab. Dispos 32:647–60
   PubMed Web of Science ®Google Scholar
• Veronese ML, Gillen LP, Dorval EP, et al. (2003). Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol 43:1091–100
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discovery 4:825–33
   PubMed Web of Science ®Google Scholar
• Xu L, Chen Y, Pan Y, et al. (2009). Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 37:2330–9
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, et al. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–19
   PubMed Web of Science ®Google Scholar
• Zimmerlin A, Trunzer M, Faller B. (2011). CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab. Dispos 39:1039–46
   PubMed Web of Science ®Google Scholar